Historical Stock Chart
5 Years : From Jan 2013 to Jan 2018
GlaxoSmithKline PLC (GSK.LN) and Human Genome Sciences (HGSI) Thursday announced that dosing has been initiated in BLISS-SC, a new Phase III trial to evaluate the efficacy, safety and tolerability of BENLYSTA administered subcutaneously once-weekly to autoantibody-positive adults with active systemic lupus erythematosus, or SLE.
-Study to enrol over 800 adult patients with SLE
-Will evaluate once-weekly subcutaneous injections of an investigational formulation of belimumab plus standard of care vs. placebo plus standard of care
-GlaxoSmithKline shares at 1210 GMT up 1.32% at GBP14.6 valuing the company at GBP73.5 billion.
-By Jana Weigand, Dow Jones Newswires; 44-20-7842-9314; email@example.com